CRAC inhibitor

SI-6869

CRAC inhibitor, >98% (HPLC)

IUPAC Name : 2,6-Difluoro-N-(2'-methyl-3'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)benzamide

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
5MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
10MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
25MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
50MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
100MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026

Applications : This is a next‑generation small‑molecule CRAC inhibitor identified through systematic SAR optimization. It exhibits strong in vivo activity in RA models, a clean safety margin, and reliable oral exposure. Phase 1 evaluation in healthy volunteers demonstrated excellent safety, tolerability, and measurable target engagement via IL‑2 and TNF‑α suppression.

References : Khedkar R. N. et al.: J. Med. Chem., 64(23), 17004–17030, 2021.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.